Kalvista Pharmaceuticals Inc (KALV NASDAQ) stock market data APIs
$10.9608
0.09(0.8%)
as of October 23, 2025
Try our APIs with
free plan!
Kalvista Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Prev. Close
10.9608
Open
11.0535
High
11.1956
Low
10.8706
52 wk Range
7.3-17.28
Market Cap
562 M
Shares Outstanding
50 523 K
Revenue
1 426 K
EPS
-1.12
Beta
-0.15
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kalvista Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kalvista Pharmaceuticals Inc data using free add-ons & libraries
Get Kalvista Pharmaceuticals Inc Fundamental Data
Kalvista Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 1 426 K
- EBITDA: -201 820 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-03
- EPS/Forecast: -0.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kalvista Pharmaceuticals Inc News
New
KalVista prices upsized offering of $125M of 3.250% notes due 2031
* KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) announced [https://seekingalpha.com/pr/20243780-kalvista-prices-upsized-offering-of-125_0-million-of-3_250-percent-con...
KalVista to offer $110M in convertible notes; shares down 10%
* KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) plans to offer $110M in convertible senior notes due 2031 via private placement. * An additional $15M in notes may b...
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs
[Wooden Approved Stamp] kemalbas KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) and Ionis Pharmaceuticals (NASDAQ:IONS [https://seekingalpha.com/symbol/IONS]) announced...
Morning Movers: Kroger rises following second quarter results
Stock futures are slightly higher following inflation data that could influence the Federal Reserve’s next move. Producer price figures yesterday came in softer than expected, reinforcing expectatio...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
